Leerink Partners Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $40

Benzinga · 2d ago
Leerink Partners analyst Andrew Berens maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and raises the price target from $34 to $40.